Table 1 Association between the study variables and the emergence of HIV-1 drug resistance
Study variables | HIV drug resistance | P value | |||
|---|---|---|---|---|---|
DRAMs, N (%) | No DRAMs, N (%) | Total N (%) | |||
Study groups | 1 (ART with prophylaxis) | 8(32) | 17(68) | 25(21.6) | .002a |
2 (Drug-Naïve) | 4(15) | 22(85) | 26(22.4) | ||
3 (ART with no prophylaxis) | 3(5) | 62(95) | 65(56.0) | ||
Duration on art (Groups 1 & 3) | < 1 Year | 4(16.7) | 20(83.3) | 24(26.7) | .624a |
1-2 Years | 5(12.5) | 35(87.5) | 40(44.4) | ||
≥ 3 Years | 2(7.7) | 24(92.3) | 26(28.9) | ||
Who clinical staging | 1 | 9(23.7) | 29(76.3) | 38(32.8) | .113a |
2 | 4(8.3) | 44(91.7) | 48(41.4) | ||
3 | 2(7.1) | 26(92.9) | 28(24.1) | ||
4 | 0(0) | 2(100) | 2(1.7) | ||
Adherence | Yes | 10 (12.0) | 73 (88.0) | 83(92.2) | .560a |
No | 1 (14.3) | 6 (85.7) | 7(7.8) | ||